BioSpace News Archive

BioCapital

AsclepiX Launches with $35 Million to Study Diseases of the Eye and Cancer

Baltimore-based AsclepiX Therapeutics closed a $35 million Series A financing.

June 24, 2020
·
3 min read
·
Mark Terry
Drug Development

New Data Shows 718 Pipeline Drugs Now Associated with COVID-19

New information released Tuesday by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19. In addition, 70% of these products are in the discovery or preclinical stages.

June 24, 2020
·
3 min read
·
Krystle Vermes
Business

Fauci, Other Top Healthcare Officials Outline Necessary Strategies to Combat COVID-19

Speaking before Congress on Tuesday, Dr. Anthony Fauci urged people to adopt strategies that involve wearing a mask in public, maintaining social distance and avoiding large gatherings of people.

June 24, 2020
·
3 min read
·
Alex Keown
Business

Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases

Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs.

June 24, 2020
·
3 min read
·
Mark Terry
Business

BIO to Outline Key Priorities for Next Pandemic During Senate Hearing

COVID-19-related testimonies will continue in Congress today, with representatives from the Biotechnology Innovation Organization (BIO) expected to address the current pandemic as well as key priorities that will need to be in place in order to effectively respond to the next global viral threat.

June 24, 2020
·
3 min read
·
Alex Keown
Drug Development

FDA Approves Phase III Study of Fulcrum’s Losmapimod in COVID-19

Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19.

June 24, 2020
·
3 min read
·
Alex Keown
BioSpace Global Roundup, June 25

Biopharma and life sciences companies provide updates on their pipelines and business plans.

June 24, 2020
·
7 min read
·
Alex Keown
vfCRISPR Uses Light to Bring Precision and Speed to Gene Editing

Light-activated CRISPR technology edits genes more precisely and faster than the more standard chemical methods, and enables “super-fast” DNA repair, according to research from Johns Hopkins University School of Medicine.

June 24, 2020
·
3 min read
·
Gail Dutton
Policy

Mayne Pharma Announces FDA Filing Acceptance of New Drug Application for E4/DRSP in the US

Mayne Pharma Group Limited is pleased to announce the New Drug Application for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration.

June 24, 2020
·
3 min read
Business

Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee

To develop its registration trial of AK104 (Bi-specific Anti-PD1/CTLA-4 Antibody) in Cervical Cancer

June 24, 2020
·
4 min read